ReviewProbiotics and antimicrobial proteins2021
Gut Microbiota is an Important Source of Bacteriocins and Their In Situ Expression Can Be Explored for Treatment of Bacterial Infections.
Review in Probiotics and antimicrobial proteins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent Advances in Exploring Casein Peptide Regulation of Inflammatory Bowel Disease from an Intestinal Barrier Perspective: Correlations, Mechanisms, Challenges and Solutions.Foods (Basel, Switzerland) · 2026Review
- The Human Gut Microbiota: A Dynamic Biologic Factory.Advances in biochemical engineering/biotechnology · 2025Review
- Review
- Gut Distribution, Impact Factor, and Action Mechanism of Bacteriocin-Producing Beneficial Microbes as Promising Antimicrobial Agents in Gastrointestinal Infection.Probiotics and antimicrobial proteins · 2024Review
- Classification and Multi-Functional Use of Bacteriocins in Health, Biotechnology, and Food Industry.Antibiotics (Basel, Switzerland) · 2024Review
- Evaluation of Safety and Probiotic Traits from a Comprehensive Genome-Based In Silico Analysis ofFoods (Basel, Switzerland) · 2023Article
- Effect of Bacteriocins on the Intestinal Microbiota.The Eurasian journal of medicine · 2023Article
- Purification, Characterization, Mode of Action, and Application of Jileicin, a Novel Antimicrobial fromJournal of agricultural and food chemistry · 2022Article
- Supplementation with honeysuckle extract improves growth performance, immune performance, gut morphology, and cecal microbes in geese.Frontiers in veterinary science · 2022Article
- Lacticaseicin 30 and Colistin as a Promising Antibiotic Formulation against Gram-Negative β-Lactamase-Producing Strains and Colistin-Resistant Strains.Antibiotics (Basel, Switzerland) · 2021Article
- Current Knowledge of the Mode of Action and Immunity Mechanisms of LAB-Bacteriocins.Microorganisms · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteriocins are interesting natural antimicrobial peptides that could be deployed quickly to combat certain antimicrobial-resistant bacterial infections. These molecules could be used in conjunction with traditional antibiotics, or even to replace them in some circumstances. To strengthen the concept of "bacteriocinotherapy," we discuss here the benefits associated with production in situ of bacteriocins by commensal bacteria. This on sites production capacity could augment the gut microbiota global resistance plan and provide a backup for bacterial infection treatments.
Indexed as
Identifiers
34523112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.